Pancreatitis News and Research

RSS
Pancreatitis is inflammation of the pancreas. The pancreas is a large gland behind the stomach and close to the duodenum—the first part of the small intestine. The pancreas secretes digestive juices, or enzymes, into the duodenum through a tube called the pancreatic duct. Pancreatic enzymes join with bile—a liquid produced in the liver and stored in the gallbladder—to digest food. The pancreas also releases the hormones insulin and glucagon into the bloodstream. These hormones help the body regulate the glucose it takes from food for energy.

Normally, digestive enzymes secreted by the pancreas do not become active until they reach the small intestine. But when the pancreas is inflamed, the enzymes inside it attack and damage the tissues that produce them.

Pancreatitis can be acute or chronic. Either form is serious and can lead to complications. In severe cases, bleeding, infection, and permanent tissue damage may occur.
New antioxidant biomaterial may provide relief to people living with chronic pancreatitis

New antioxidant biomaterial may provide relief to people living with chronic pancreatitis

Insurance denials hinder GLP1Ra use in children and teens with type 2 diabetes

Insurance denials hinder GLP1Ra use in children and teens with type 2 diabetes

GLP-1 drugs may reduce pancreatitis risk in obese and diabetic patients

GLP-1 drugs may reduce pancreatitis risk in obese and diabetic patients

Statins found to prevent chronic inflammation-related cancers by inhibiting interleukin-33

Statins found to prevent chronic inflammation-related cancers by inhibiting interleukin-33

Statins may block an inflammation pathway involved in the development of cancer

Statins may block an inflammation pathway involved in the development of cancer

GLP-1 receptor agonists effective for weight loss in obesity without diabetes

GLP-1 receptor agonists effective for weight loss in obesity without diabetes

Key studies on GLP-1 drugs, alpha-gal syndrome, and liver disease medications to be presented at DDW 2024

Key studies on GLP-1 drugs, alpha-gal syndrome, and liver disease medications to be presented at DDW 2024

Does diabetes increase the risk of long COVID?

Does diabetes increase the risk of long COVID?

Phase 2 trial reveals Lixisenatide may reduce motor disability in Parkinson’s patients

Phase 2 trial reveals Lixisenatide may reduce motor disability in Parkinson’s patients

Investigational drug plozasiran shows promise in reducing severe hypertriglyceridemia

Investigational drug plozasiran shows promise in reducing severe hypertriglyceridemia

Breakthrough research could transform the landscape of ovarian cancer treatment

Breakthrough research could transform the landscape of ovarian cancer treatment

Circulatory cholesterol levels are inversely linked to mortality of patients with sepsis and critical illness

Circulatory cholesterol levels are inversely linked to mortality of patients with sepsis and critical illness

New insights on better diagnosis and treatment of ischemic cholecystitis

New insights on better diagnosis and treatment of ischemic cholecystitis

Metabolic syndrome linked to higher pancreatic cancer risk, study shows

Metabolic syndrome linked to higher pancreatic cancer risk, study shows

Mendelian randomization reveals a causal relationship between diabetes mellitus and pancreatic cancer

Mendelian randomization reveals a causal relationship between diabetes mellitus and pancreatic cancer

Breakthrough AI tool PANDA shows promise in early detection of pancreatic cancer using non-contrast CT

Breakthrough AI tool PANDA shows promise in early detection of pancreatic cancer using non-contrast CT

Breakthrough in tuberculosis treatment: TB-PRACTECAL trial reveals efficacy of new oral regimen

Breakthrough in tuberculosis treatment: TB-PRACTECAL trial reveals efficacy of new oral regimen

SELECT trial: Semaglutide reduces cardiovascular events by 20% in overweight or obese patients without diabetes

SELECT trial: Semaglutide reduces cardiovascular events by 20% in overweight or obese patients without diabetes

Study identifies predictors of opioid overdose after prescription for chronic pain

Study identifies predictors of opioid overdose after prescription for chronic pain

GLP-1 weight loss drugs linked to heightened GI risks, says new study

GLP-1 weight loss drugs linked to heightened GI risks, says new study

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.